CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...

The country’s Medicines and Healthcare products Regulatory Agency’s Yellow Card scheme, the UK’s official system for ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

This is Prime Therapeutics’ latest research into GLP-1s and the long term impact of taking the medication. In October of last ...

GLP-1 drugs like Ozempic® and Zepbound® have gained significant attention for treating both diabetes and assisting with weight loss.

A new oral drug may be able to treat type 2 diabetes and obesity without impacting muscle mass as an alternative to GLP-1 ...

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan ...

As Ohio cuts off state employees' coverage of medications for weight loss, a lawmaker who has benefited from the drugs wants ...